Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гормональные и эмбриологические параметры циклов овариальной стимуляции при использовании дидрогестерона для предотвращения преждевременного пика лютеинизирующего гормона
Гормональные и эмбриологические параметры циклов овариальной стимуляции при использовании дидрогестерона для предотвращения преждевременного пика лютеинизирующего гормона
Корнеева И.Е., Ковальчук А.И., Назаренко Т.А., Митюрина Е.В., Перминова С.Г., Бачурин А.В., Иванец Т.Ю. Гормональные и эмбриологические параметры циклов овариальной стимуляции при использовании дидрогестерона для предотвращения преждевременного пика лютеинизирующего гормона. Гинекология. 2022;24(5):380–385. DOI: 10.26442/20795696.2022.5.201675
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Оценить эффекты протокола овариальной стимуляции с назначением дидрогестерона для предотвращения преждевременного пика лютеинизирующего гормона (ЛГ) на гормональные и эмбриологические параметры программы экстракорпорального оплодотворения (ЭКО)/ИКСИ (интрацитоплазматической инъекции сперматозоида).
Материалы и методы. Всего 79 женщинам с бесплодием и сохраненным овариальным резервом проводили овариальную стимуляцию в программе ЭКО/ИКСИ. В 1-й группе (n=38) для предотвращения преждевременного пика ЛГ использовали дидрогестерон, во 2-й группе (n=41) – антагонист гонадотропин-рилизинг-гормона (антГнРГ). Сравнивали параметры стимулированных циклов: стартовые и курсовые дозы гонадотропинов, длительность стимуляции, гормональные и эмбриологические показатели (число полученных и зрелых ооцитов, частоту оплодотворения, количество бластоцист и криоконсервированных эмбрионов).
Результаты. Пациентки обеих групп были сопоставимы по возрасту – 34,3±3,32 и 33,4±3,42 года, индексу массы тела – 24,1±2,1 и 23,3±1,9, уровню антимюллерова гормона – 2,6±1,11 и 2,8±1,43 нг/мл и количеству антральных фолликулов по данным УЗИ – 6,22±1,21 и 7,13±0,89 соответственно в 1 и 2-й группах. Гормональные параметры циклов овариальной стимуляции с назначением дидрогестерона или антГнРГ характеризовались сопоставимыми данными, касающимися курсовой дозы гонадотропина, продолжительности дней стимуляции, концентрации ЛГ и стероидных гормонов в сыворотке крови. Показатели эмбриологического этапа программы (число полученных и зрелых ооцитов, бластоцист и криоконсервированных эмбрионов) не имели значимых межгрупповых различий, несмотря на высокий уровень прогестерона в сыворотке крови у женщин, принимавших дидрогестерон.
Заключение. Протокол с дидрогестероном не уступает стандартному протоколу с антГнРГ по общепринятым клинико-лабораторным и эмбриологическим показателям. Пероральный прием препарата позволяет уменьшить количество инъекций в цикле лечения и быть более удобным для пациентов, не планирующих перенос эмбрионов.
Ключевые слова: овариальная стимуляция, антагонист гонадотропин-рилизинг-гормона, прогестерон, дидрогестерон, экстракорпоральное оплодотворение
Materials and methods. A prospective study randomised, including 79 women with normal ovarian reserve undergoing ovarian stimulation for IVF/ICSI with recombinant FSH (rFSH) from Day 2 or 3 of the menstrual cycle. To prevent the premature LH surge, participants in Group 1 (n=38) received oral dydrogesterone 20 mg/day from the start of ovarian stimulation until the day of ovulation trigger administration. Participants in Group 2 (n=41) received a GnRH antagonist. We evaluated the starting and total dose of gonadotropins, duration of stimulation, serum levels of LH, oestradiol and progesterone on Day 1 and 6 of stimulation and the day of trigger administration, number of retrieved and mature oocytes, fertilization rate, and the number of blastocysts and cryopreserved embryos.
Results. There were no significant differences in most hormonal parameters, characteristics of the ovarian stimulation and embryological outcomes between the two groups. Serum levels of progesterone in the dydrogesterone arm were higher than in the GnRH antagonist arm (2.3 nmol/l [2.0–3.4] vs 1.5 [1.0–2.4] nmol/l; p=0.026), but without any impact on the embryological outcomes.
Conclusion. Prevention of premature LH surge in ovarian stimulation cycles using oral dydrogesterone may represent a convenient alternative to the conventional use of GnRH antagonists, reducing the number of required injections and potentially increasing the convenience in patients who are not planning a fresh embryo transfer.
Keywords: ovarian stimulation, gonadotrophin-releasing hormone antagonist, progesterone, dydrogesterone, in vitro fertilization
Материалы и методы. Всего 79 женщинам с бесплодием и сохраненным овариальным резервом проводили овариальную стимуляцию в программе ЭКО/ИКСИ. В 1-й группе (n=38) для предотвращения преждевременного пика ЛГ использовали дидрогестерон, во 2-й группе (n=41) – антагонист гонадотропин-рилизинг-гормона (антГнРГ). Сравнивали параметры стимулированных циклов: стартовые и курсовые дозы гонадотропинов, длительность стимуляции, гормональные и эмбриологические показатели (число полученных и зрелых ооцитов, частоту оплодотворения, количество бластоцист и криоконсервированных эмбрионов).
Результаты. Пациентки обеих групп были сопоставимы по возрасту – 34,3±3,32 и 33,4±3,42 года, индексу массы тела – 24,1±2,1 и 23,3±1,9, уровню антимюллерова гормона – 2,6±1,11 и 2,8±1,43 нг/мл и количеству антральных фолликулов по данным УЗИ – 6,22±1,21 и 7,13±0,89 соответственно в 1 и 2-й группах. Гормональные параметры циклов овариальной стимуляции с назначением дидрогестерона или антГнРГ характеризовались сопоставимыми данными, касающимися курсовой дозы гонадотропина, продолжительности дней стимуляции, концентрации ЛГ и стероидных гормонов в сыворотке крови. Показатели эмбриологического этапа программы (число полученных и зрелых ооцитов, бластоцист и криоконсервированных эмбрионов) не имели значимых межгрупповых различий, несмотря на высокий уровень прогестерона в сыворотке крови у женщин, принимавших дидрогестерон.
Заключение. Протокол с дидрогестероном не уступает стандартному протоколу с антГнРГ по общепринятым клинико-лабораторным и эмбриологическим показателям. Пероральный прием препарата позволяет уменьшить количество инъекций в цикле лечения и быть более удобным для пациентов, не планирующих перенос эмбрионов.
Ключевые слова: овариальная стимуляция, антагонист гонадотропин-рилизинг-гормона, прогестерон, дидрогестерон, экстракорпоральное оплодотворение
________________________________________________
Materials and methods. A prospective study randomised, including 79 women with normal ovarian reserve undergoing ovarian stimulation for IVF/ICSI with recombinant FSH (rFSH) from Day 2 or 3 of the menstrual cycle. To prevent the premature LH surge, participants in Group 1 (n=38) received oral dydrogesterone 20 mg/day from the start of ovarian stimulation until the day of ovulation trigger administration. Participants in Group 2 (n=41) received a GnRH antagonist. We evaluated the starting and total dose of gonadotropins, duration of stimulation, serum levels of LH, oestradiol and progesterone on Day 1 and 6 of stimulation and the day of trigger administration, number of retrieved and mature oocytes, fertilization rate, and the number of blastocysts and cryopreserved embryos.
Results. There were no significant differences in most hormonal parameters, characteristics of the ovarian stimulation and embryological outcomes between the two groups. Serum levels of progesterone in the dydrogesterone arm were higher than in the GnRH antagonist arm (2.3 nmol/l [2.0–3.4] vs 1.5 [1.0–2.4] nmol/l; p=0.026), but without any impact on the embryological outcomes.
Conclusion. Prevention of premature LH surge in ovarian stimulation cycles using oral dydrogesterone may represent a convenient alternative to the conventional use of GnRH antagonists, reducing the number of required injections and potentially increasing the convenience in patients who are not planning a fresh embryo transfer.
Keywords: ovarian stimulation, gonadotrophin-releasing hormone antagonist, progesterone, dydrogesterone, in vitro fertilization
Полный текст
Список литературы
1. Mascarenhas MN, Flaxman SR, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. DOI:10.1371/journal.pmed.1001356
2. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008-11. DOI:10.1016/j.fertnstert.2014.01.019
3. Griesinger G, Schultz L, Bauer T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric st. Fertil Steril. 2011;95(6):2029-33.e1. DOI:10.1016/j.fertnstert.2011.01.163
4. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed. 2019;39(2):321-31. DOI:10.1016/j.rbmo.2019.03.212
5. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2007;92(9):3582-9. DOI:10.1210/jc.2006-2816
6. Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105-11. DOI:10.1016/j.fertnstert.2013.09.007
7. Wang N, Wang Y, Chen Q, et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016;84(5):720-8. DOI:10.1111/cen.12983
8. Richter TA, Robinson JE, Evans NP. Progesterone Blocks the Estradiol-Stimulated Luteinizing Hormone Surge by Disrupting Activation in Response to a Stimulatory Estradiol Signal in the Ewe1. Biol Reprod. 2002;67(1):119-25. DOI:10.1095/biolreprod67.1.119
9. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. DOI:10.1016/j.fertnstert.2015.03.022
10. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-37. DOI:10.1093/humrep/dex367
11. Wang Y, Chen Q, Wang N, et al. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF. Medicine (Baltimore). 2016;95(9):e2939. DOI:10.1097/MD.0000000000002939
12. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(9):7-16. DOI:10.1016/j.maturitas.2003.09.014
13. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(9):S3-S11. DOI:10.1016/j.maturitas.2009.10.011
14. Nadarajah R, Rajesh H, Wong K, et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017;58(6):294-7. DOI:10.11622/smedj.2016080
15. Huang J, Xie Q, Lin J, et al. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2020;13:4461-70. DOI:10.2147/DDDT.S230129
16. Eftekhar M, Hoseini M, Saeed L. Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int J Reprod Biomed. 2019;13:4461-70. DOI:10.18502/ijrm.v17i9.5103
17. Iwami N, Kawamata M, Ozawa N, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-71. DOI:10.1007/s00404-018-4856-8
18. Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46(8):1403-11. DOI:10.1111/jog.14267
2. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008-11. DOI:10.1016/j.fertnstert.2014.01.019
3. Griesinger G, Schultz L, Bauer T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric st. Fertil Steril. 2011;95(6):2029-33.e1. DOI:10.1016/j.fertnstert.2011.01.163
4. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed. 2019;39(2):321-31. DOI:10.1016/j.rbmo.2019.03.212
5. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2007;92(9):3582-9. DOI:10.1210/jc.2006-2816
6. Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105-11. DOI:10.1016/j.fertnstert.2013.09.007
7. Wang N, Wang Y, Chen Q, et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016;84(5):720-8. DOI:10.1111/cen.12983
8. Richter TA, Robinson JE, Evans NP. Progesterone Blocks the Estradiol-Stimulated Luteinizing Hormone Surge by Disrupting Activation in Response to a Stimulatory Estradiol Signal in the Ewe1. Biol Reprod. 2002;67(1):119-25. DOI:10.1095/biolreprod67.1.119
9. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. DOI:10.1016/j.fertnstert.2015.03.022
10. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-37. DOI:10.1093/humrep/dex367
11. Wang Y, Chen Q, Wang N, et al. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF. Medicine (Baltimore). 2016;95(9):e2939. DOI:10.1097/MD.0000000000002939
12. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(9):7-16. DOI:10.1016/j.maturitas.2003.09.014
13. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(9):S3-S11. DOI:10.1016/j.maturitas.2009.10.011
14. Nadarajah R, Rajesh H, Wong K, et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017;58(6):294-7. DOI:10.11622/smedj.2016080
15. Huang J, Xie Q, Lin J, et al. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2020;13:4461-70. DOI:10.2147/DDDT.S230129
16. Eftekhar M, Hoseini M, Saeed L. Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int J Reprod Biomed. 2019;13:4461-70. DOI:10.18502/ijrm.v17i9.5103
17. Iwami N, Kawamata M, Ozawa N, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-71. DOI:10.1007/s00404-018-4856-8
18. Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46(8):1403-11. DOI:10.1111/jog.14267
2. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008-11. DOI:10.1016/j.fertnstert.2014.01.019
3. Griesinger G, Schultz L, Bauer T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric st. Fertil Steril. 2011;95(6):2029-33.e1. DOI:10.1016/j.fertnstert.2011.01.163
4. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed. 2019;39(2):321-31. DOI:10.1016/j.rbmo.2019.03.212
5. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2007;92(9):3582-9. DOI:10.1210/jc.2006-2816
6. Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105-11. DOI:10.1016/j.fertnstert.2013.09.007
7. Wang N, Wang Y, Chen Q, et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016;84(5):720-8. DOI:10.1111/cen.12983
8. Richter TA, Robinson JE, Evans NP. Progesterone Blocks the Estradiol-Stimulated Luteinizing Hormone Surge by Disrupting Activation in Response to a Stimulatory Estradiol Signal in the Ewe1. Biol Reprod. 2002;67(1):119-25. DOI:10.1095/biolreprod67.1.119
9. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. DOI:10.1016/j.fertnstert.2015.03.022
10. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-37. DOI:10.1093/humrep/dex367
11. Wang Y, Chen Q, Wang N, et al. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF. Medicine (Baltimore). 2016;95(9):e2939. DOI:10.1097/MD.0000000000002939
12. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(9):7-16. DOI:10.1016/j.maturitas.2003.09.014
13. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(9):S3-S11. DOI:10.1016/j.maturitas.2009.10.011
14. Nadarajah R, Rajesh H, Wong K, et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017;58(6):294-7. DOI:10.11622/smedj.2016080
15. Huang J, Xie Q, Lin J, et al. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2020;13:4461-70. DOI:10.2147/DDDT.S230129
16. Eftekhar M, Hoseini M, Saeed L. Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int J Reprod Biomed. 2019;13:4461-70. DOI:10.18502/ijrm.v17i9.5103
17. Iwami N, Kawamata M, Ozawa N, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-71. DOI:10.1007/s00404-018-4856-8
18. Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46(8):1403-11. DOI:10.1111/jog.14267
________________________________________________
2. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008-11. DOI:10.1016/j.fertnstert.2014.01.019
3. Griesinger G, Schultz L, Bauer T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric st. Fertil Steril. 2011;95(6):2029-33.e1. DOI:10.1016/j.fertnstert.2011.01.163
4. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed. 2019;39(2):321-31. DOI:10.1016/j.rbmo.2019.03.212
5. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2007;92(9):3582-9. DOI:10.1210/jc.2006-2816
6. Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014;101(1):105-11. DOI:10.1016/j.fertnstert.2013.09.007
7. Wang N, Wang Y, Chen Q, et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016;84(5):720-8. DOI:10.1111/cen.12983
8. Richter TA, Robinson JE, Evans NP. Progesterone Blocks the Estradiol-Stimulated Luteinizing Hormone Surge by Disrupting Activation in Response to a Stimulatory Estradiol Signal in the Ewe1. Biol Reprod. 2002;67(1):119-25. DOI:10.1095/biolreprod67.1.119
9. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. DOI:10.1016/j.fertnstert.2015.03.022
10. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-37. DOI:10.1093/humrep/dex367
11. Wang Y, Chen Q, Wang N, et al. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF. Medicine (Baltimore). 2016;95(9):e2939. DOI:10.1097/MD.0000000000002939
12. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(9):7-16. DOI:10.1016/j.maturitas.2003.09.014
13. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(9):S3-S11. DOI:10.1016/j.maturitas.2009.10.011
14. Nadarajah R, Rajesh H, Wong K, et al. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2017;58(6):294-7. DOI:10.11622/smedj.2016080
15. Huang J, Xie Q, Lin J, et al. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2020;13:4461-70. DOI:10.2147/DDDT.S230129
16. Eftekhar M, Hoseini M, Saeed L. Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: An RCT. Int J Reprod Biomed. 2019;13:4461-70. DOI:10.18502/ijrm.v17i9.5103
17. Iwami N, Kawamata M, Ozawa N, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-71. DOI:10.1007/s00404-018-4856-8
18. Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46(8):1403-11. DOI:10.1111/jog.14267
Авторы
И.Е. Корнеева, А.И. Ковальчук*, Т.А. Назаренко, Е.В. Митюрина, С.Г. Перминова, А.В. Бачурин, Т.Ю. Иванец
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*kovalchukalla27@mail.ru
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*kovalchukalla27@mail.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*kovalchukalla27@mail.ru
________________________________________________
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*kovalchukalla27@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.